Employees: 276
Size Abbisko Cayman (2256.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $578M, the 713th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$6.30 on 18 Nov 2026.
Performance Over six months the shares fell 38.7%, against -23.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue fell 83.3% over the last twelve months (peer median +2.2%); the operating margin is -519.6% (peer median 5.6%).
Valuation It trades at 20.1× enterprise value to sales against a peer median of 3.1× (4th most expensive of 17).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$111M | HK$664M | HK$546M | HK$21.1M | HK$0 |
| Revenue growth | — | +21% | +2,495% | — | — |
| Gross profit | HK$84.8M | HK$640M | HK$521M | HK$704,989 | -HK$18.4M |
| EBITDA | -HK$552M | HK$54.5M | HK$2.14M | -HK$544M | -HK$560M |
| Net income | -HK$520M | HK$59.9M | HK$30.7M | -HK$477M | -HK$576M |
| Free cash flow | -HK$390M | HK$142M | HK$40.4M | -HK$443M | -HK$399M |
| Capital expenditure | HK$4.70M | HK$6.00M | HK$8.02M | HK$13.5M | HK$26.5M |
| Total debt | n/a | HK$338M | HK$25.8M | HK$39.3M | HK$51.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2256.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.9% | -11.1% | 6th lowest of 21 |
| 6-month return | -38.7% | -23.4% | 5th lowest of 21 |
| Distance from 52-week high | -58.0% | -43.4% | 5th lowest of 21 |
| Revenue growth (TTM) | -83.3% | +2.2% | 2nd lowest of 18 |
| Operating margin | -519.6% | 5.6% | 4th lowest of 17 |
| EV / Sales | 20.1× | 3.1× | 4th most expensive of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Abbisko Cayman 2256.HK | Hong Kong | $578M | -39% | -83% | -520% | 20.1× | n/a | n/a |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $577M | -26% | -21% | 32% | 1.9× | -15.4% | +2.8% |
| Oneness Biotech 4743.TWO | Taiwan | $580M | -13% | +19% | -589% | 101.5× | n/a | n/a |
| Lepu Biopharma 2157.HK | Hong Kong | $580M | -43% | +47% | 7% | 4.5× | n/a | n/a |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $583M | -20% | -6% | 5% | 2.6× | 20.9% | +21.9% |
| Cullinan Therapeutics CGEM | United States | $585M | -37% | n/a | n/a | n/a | n/a | n/a |
| Alumis ALMS | United States | $569M | -80% | -67% | -5,375% | 23.9× | n/a | n/a |
| Entera Bio ENTX | United States | $568M | +163% | -100% | n/a | n/a | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $591M | -41% | +3% | -39% | 3.7× | 50.4% | -12.3% |
| Jenkem Technology 688356.SS | China | $563M | -30% | +52% | 11% | 8.7× | 36.4% | +11.2% |
| Zhong Zhu Healthcare 600568.SS | China | $562M | -22% | -6% | -34% | 6.2× | n/a | n/a |
| Immix Biopharma IMMX | United States | $596M | -20% | n/a | n/a | n/a | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $598M | -14% | -2% | 8% | 0.9× | -6.2% | +6.5% |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $557M | -24% | -3% | 7% | 1.2× | -5.8% | +4.1% |
| Aclaris Therapeutics ACRS | United States | $555M | -23% | -59% | -1,412% | 69.1× | n/a | n/a |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $602M | -38% | +5% | -30% | 7.5× | n/a | n/a |
| Boryung 003850.KS | South Korea | $554M | -13% | +6% | 6% | 0.9× | -3.1% | +12.6% |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $604M | -31% | +2% | 4% | 1.2× | -0.6% | -1.6% |
| DBV Technologies DBV.PA | France | $604M | -46% | n/a | n/a | n/a | n/a | n/a |
| Zevra Therapeutics ZVRA | United States | $552M | -9% | +75% | 31% | 2.4× | -4.9% | +51.6% |
| Zeria Pharmaceutical 4559.T | Japan | $552M | -12% | +12% | 15% | 1.0× | -12.3% | +11.1% |